Omeprazol Stada (Omeprazole)

Omeprazole blocks the H+/K+ ATPase enzyme, also known as the gastric proton pump, on parietal cells. By irreversibly inhibiting this pump, it stops the final step of acid production, leading to a sustained increase in gastric pH and reduced acidity.

The appropriate dose of Omeprazol Stada is determined by the prescribing clinician based on the specific indication, patient age, renal function and treatment duration. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for omeprazole in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Omeprazol Stada belongs to the proton pump inhibitor class, which generally provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, omeprazole has a well‑established efficacy and safety profile, though individual response may vary.

Store Omeprazol Stada at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Omeprazol Stada is taken orally, usually as a whole tablet or capsule with a glass of water. It is commonly recommended to take the dose before a meal, but patients should follow the specific instructions given by their prescriber.

Serious but rare risks include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated colitis, low magnesium levels, increased risk of bone fractures with long‑term use, interstitial nephritis and significant liver enzyme elevations. Any concerning symptoms should prompt immediate medical evaluation.

Patients with known hypersensitivity to omeprazole or any component of the formulation should avoid the product. Caution is also advised for individuals with severe liver disease, certain drug interactions, or those for whom alternative acid‑reducing therapies are more appropriate, as determined by a healthcare professional.